TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07622121: Treatment of Chronic Thyroid Eye Disease With MHB018A

Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 135 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07622121 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07622121 Rescue Dossier →